marciobrito

9 POSTS 0 COMMENTS

Ongoing venous stent trials will soon provide vital comparative data

While comparative study data for venous stents are still lacking, results of a number of ongoing and planned venous stent trials will increase the...

New research indicates that stenting below the inguinal ligament does not...

Endovascular treatment of iliocaval and infrainguinal post-thrombotic venous obstruction results do not appear to be adversely affected by extension of the iliac vein stents...

FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...

Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...

Inari Medical announces completion of enrolment in the FLARE study for...

Inari Medical has announced that it has completed enrolment of its investigational device exemption (IDE) study. The FlowTriever Pulmonary Embolectomy Clinical Study (FLARE) study...

Kathleen Gibson: VeClose study three-year results

Kathleen Gibson, Bellevue, USA, presented the three-year results of the VeClose clinical trial at the recent Charing Cross Symposium. Gibson spoke to Venous News...

Inari Medical announces first patient treated with the ClotTriever thrombectomy system

Inari Medical, a venture capital backed medical device company focused on the interventional treatment of venous thrombus, has announced the treatment of the first...

Advances and challenges in the treatment of deep vein thrombosis

The goal of management of venous thromboembolic disease is to prevent thrombus extension or embolisation and to prevent early and late episodes of recurrence....

Two new real-world studies confirm positive efficacy and safety profile of...

Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...

Varithena earns FDA approval for 30-day post-activation shelf life

BTG has announced that the US Food and Drug Administration (FDA) has approved an extension of the post-activation shelf life of Varithena (polidocanol injectable foam)...